Fabhalta (iptacopan) appears to outperform Empaveli (pegcetacoplan) in raising hemoglobin levels and reducing the need for blood transfusions in adults with paroxysmal nocturnal hemoglobinuria (PNH) who continue to have symptoms despite previous treatment. Those are the findings of a new study that indirectly compared the two approved…
Biogen has entered into an agreement to acquire Apellis Pharmaceuticals, adding Empaveli (pegcetacoplan), marketed in Europe as Aspaveli, to its portfolio for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and two other rare diseases involving abnormal complement activation, which is part of the immune system. For Biogen,…
Discussion
One of the hardest lessons that comes with living with paroxysmal nocturnal hemoglobinuria (PNH) is learning that control doesn’t always look the way you thought it would. Before a PNH diagnosis, control can feel straightforward. You plan your days, set your goals, and expect your body to cooperate.
The approved dosing regimens of Voydeya (danicopan) are supported for adults with paroxysmal nocturnal hemoglobinuria (PNH) receiving standard therapies and generally do not appear to require adjustment based on patient characteristics or food intake, according to a new analysis of clinical trial data. Voydeya is an oral medication…
Get regular updates delivered to your inbox.
